AstraZeneca's Fasenra (benralizumab) Fails Ph III Trial for COPD

AstraZeneca and MedImmune, announced on 5/11/18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD.